I started my career as a digital pharma marketer. At the time, I believed that DTC was essential to inform and educate people, but today’s DTC is everywhere, even in health conditions that have small patient populations. I’ve worked with clients who have tried to keep data that their DTC TV spots aren’t effective. That’s when I try to educate and inform them about the power of online health searches, but working in digital today can be complicated and hard to measure.

Pharma companies argue they’re educating patients. Marketing critics argue DTC is manipulative. Both sides are right, to a point. But there’s an important question no one is asking:

Why has our healthcare system become so reliant on marketing efforts to begin with?

America is one of two countries that allow the direct-to-consumer advertisement of prescription drugs. Patients see an estimated 4.5 million prescription drug TV ads per year, according to Kantar Media, and the industry spends billions each year on consumer advertising and physician promotion.

The outcome should surprise no one: Patients arrive at doctors’ offices demanding name-brand drugs they’ve seen on TV commercials instead of discussing treatment options that may be better suited for their condition.

It’s also one of the only markets where consumers can request products they cannot buy, providers can prescribe products they don’t pay for, insurers cover most of the costs, and behind-the-scenes pharmacy benefit managers negotiate drug rebates that no one fully understands.

In a system this distorted, pharma marketing doesn’t just drive patient demand—it replaces price competition. Pharma knows this.

When manufacturers hide list prices, negotiate confidential rebates, providers order medicines patients don’t pay for, and insurance protects patients from the true cost of treatment, drug companies have a powerful incentive to simply market brand awareness instead of engaging in legitimate competition.

That’s not stupid business behavior. That is completely unsustainable public policy.

Let me be clear: Pharma companies provide enormous value.

Just look at what happened with the COVID-19 vaccines. Developing lifesaving vaccines in less than a year was a remarkable achievement. Hepatitis C was once a chronic, deadly disease. Now we can cure it. Immunotherapy is revolutionizing cancer treatment. GLP-1 drugs are revolutionizing diabetes and obesity treatment, with the possibility of treating heart disease and kidney disease coming soon.

Each new breakthrough is the result of decades of basic research, financial risk, and billions of dollars of private investment. Society benefits from these innovations. We should incentivize them. In fact, we do—in theory.

The problem is, society isn’t rewarding innovation. Society is rewarding marketing.

Consider this: Pharma spends billions of dollars a year marketing drugs to physicians and patients because our healthcare system rewards good marketing over transparent competition.

If a pharma product was better than its competitors, it would sell itself. It would provide better clinical outcomes at a price patients and providers were willing to pay. But it doesn’t have to because pharmaceutical companies sell drugs to middlemen who negotiate secretive rebates and pass unclear prices onto insurers, patients, and providers.

Nobody knows the true price of anything.

Drug companies throw tens of millions of dollars at commercials, physicians, and conferences because they know that if they can sway just a few doctors and reach enough patients, they can move mountains. Or, at least, sell more drugs.

Physician marketing isn’t much better. Despite congressional transparency laws and ethical quandaries that have led hospitals to ban many sales tactics, Big Pharma still spends billions each year on physician detailing, continuing medical education, consulting fees, and sponsorships.

And doctors believe these marketing efforts don’t affect their decision-making. “Bias” suggests intentional wrongdoing. But behavioral economics has shown again and again that humans are affected by familiarity, repetition, reciprocity, and social connections.

Physicians are humans. But just because physicians might be susceptible to marketing tactics doesn’t mean Big Pharma has doctors on kickbacks (most of the time). Humans are susceptible to marketing.

We Really Have No Choice

The point isn’t to villainize drug companies. Pharma companies are profit-driven entities like any other. They do things because the policy incentives allow them to. If we want Big Pharma to change how it markets, we should change the incentives.

Make it easier for generics and biosimilars to enter the market once patents expire. Crack down on patent abuse that needlessly extends monopoly pricing. Increase price transparency across the supply chain. Ensure pharmacy benefit managers publicly report rebates and explain how they work. Make comparative effectiveness data more accessible so doctors have unbiased information when they evaluate treatment options. And let patients see what doctors see.

Let there be price competition.

The irony of this debate is that some of the biggest opponents of pharma marketing are in favor of price controls to lower drug costs. Price controls treat the symptoms of our healthcare crisis but leave the disease intact. Mandating pharmaceutical prices will reduce costs in the short-term, but it will destroy pharmaceutical companies’ incentives to innovate in the future.

Competition—not government bureaucracy—drives markets.

Pharma marketing isn’t an oxymoron.

Drug companies should absolutely be able to educate doctors about new treatments. Patients should be able to learn about illnesses they wouldn’t otherwise know about. Information is valuable. It’s what allows a free market to match supply with demand.

But once we let pharma companies fill that void with sales instead of price transparency and competition, we get ads like this:

We don’t have too much drug advertising because pharma companies are greedy. We have too much drug advertising because the healthcare industry has become one of the least price-transparent and competitive industries in the country.

Fix the former, and the latter won’t matter as much.

Until then, the next time you see a pharmaceutical ad think about this:

Patients are being sold.

The post Pharma Marketing Isn’t an Oxymoron appeared first on World of DTC Marketing.

A patient may recognize their symptoms but delay seeing a doctor. A physician may diagnose the condition but hesitate to prescribe. A prescription may be written but rejected by the insurer. An approval may finally arrive, only for the patient to abandon treatment because the instructions, side effects, or costs feel unmanageable.

No amount of advertising frequency can repair that experience.

Marketing Can’t Stop at the Prescription

Pharma marketers have traditionally treated the prescription as the finish line. In reality, it is merely one handoff in a long and increasingly fragile journey. The next competitive advantage will come from removing friction between:

• Symptoms and diagnosis
• Diagnosis and treatment
• Clinical evidence and practical understanding
• Prescription and insurance approval
• Approval and treatment initiation
• Treatment initiation and long-term adherence

Every unnecessary form, confusing instruction, unanswered question and unexpected cost weakens the brand. Patients do not separate the medicine from the experience surrounding it. If obtaining or using the treatment is exhausting, that frustration becomes part of the product. A “patient-centric” campaign means little when the patient still has to navigate a maze to receive the medication.

Comprehension Is Part of the Product

Pharma has an information problem disguised as a communication problem. Patients are often given technically accurate information that is almost impossible to use. Physicians receive an avalanche of data without enough help translating it into individual treatment decisions. Caregivers are expected to absorb complex information on dosing, safety, and access during emotionally difficult moments.

The winning brands will not simply publish more content. They will make difficult information easier to understand and act upon. That means explaining what treatment can realistically accomplish, what patients may experience, how quickly it may work, what side effects require attention, and what happens when insurance says no.

Clarity is not a creative flourish. It is a commercial capability.

Access Is Marketing

Too many organizations still treat market access, patient services, and marketing as separate disciplines. Patients experience them as one brand.

A memorable television commercial followed by weeks of prior-authorization delays is not good marketing. A compelling physician presentation followed by an unaffordable copay is not a successful promotion. A sophisticated digital campaign that drives patients into a dysfunctional support program is a waste of money.

Access is not what happens after marketing succeeds. Access determines whether marketing succeeds. Brands should be judged not only by awareness, recall, and intent, but also by how effectively people move through the treatment journey. How many prescriptions are abandoned? How long does treatment initiation take? Where do patients become confused? How often must physicians and their staff repeat the same administrative work? Those are marketing questions now.

Convenience Will Become a Clinical Differentiator

When competing treatments offer broadly comparable outcomes, the surrounding experience becomes decisive.

The easier therapy may be the one with simpler dosing, clearer education, faster onboarding, more responsive support, or fewer administrative obstacles. These advantages may not appear prominently in a clinical trial endpoint, but they matter greatly in the real world. A medicine cannot deliver value if the patient cannot obtain it, understand it, or remain on it.

Pharma companies love talking about innovation, yet often define it too narrowly. Innovation is not limited to a molecule. It can be a better enrollment process, a useful digital tool, a plain-language explanation, or a support service that solves a real problem instead of collecting patient data.

Stop Buying Attention and Start Earning Momentum

Reach and frequency will not disappear. Brands still need visibility. Physicians and patients still need to know that treatments exist. But attention without progress is increasingly worthless.

The strongest pharma brands will identify every point at which patients, caregivers and healthcare professionals become delayed, discouraged or lost—and then remove those barriers. Their marketing organizations will behave less like promotional departments and more like experience designers.

They will understand that every reduced delay is a competitive advantage. Every answered question builds confidence. Every simplified step increases the likelihood that treatment will actually begin and continue.

The next era of pharma marketing will not be won by the company that shouts the loudest or buys the most impressions. It will be won by the brands that make treatment easier to understand, obtain, and live with. In an industry addicted to adding messages, the smartest strategy may be removing obstacles.

The post Pharma Marketing’s Next Competitive Advantage: Less Friction appeared first on World of DTC Marketing.

1ne. The Mission Still Matters (To some)

One thing hasn’t changed: people genuinely believe in the industry’s purpose. Most employees consistently describe the satisfaction of contributing to therapies that improve or save lives. Whether they work in R&D, medical affairs, manufacturing, or commercial teams, many cite patient impact as the reason they stay. Purpose remains pharma’s greatest competitive advantage in attracting talent.

The downside is that employees feel there are too many “lifers” who spend their time ensuring their jobs are secure and removing threats to their status within the company. It’s more prevalent in big pharma than in biotech and can lead to an exodus of talented people.

2wo. Career Security Feels Less Certain Than It Used To

The second dominant theme is uncertainty.

Conversations that once centered on career growth have increasingly shifted toward layoffs, reorganizations, hiring freezes, and lengthy job searches. Professionals describe spending six months—or even more than a year—looking for their next role despite strong credentials. BioSpace polling, widely discussed on Reddit, reinforces these concerns, with many job seekers reporting extended searches. The perception has shifted from:

“Pharma is stable.”

to

“Pharma is rewarding—but not immune to disruption.”

3hree. Bureaucracy Is Becoming a Bigger Frustration Than Workload

Employees rarely complain about working hard. Instead, they complain about how difficult it has become to get meaningful work done. Common frustrations include:

• Too many approvals
• Endless cross-functional meetings
• Slow decision-making
• Frequent organizational changes
• Internal politics outweighing expertise

The other recurring issue is that culture fit has become more important than knowledge and experience. An MSL, for example, was told not to question the data she received as it was perceived as “disruptive”. More and more, managers want people who check boxes and won’t question anything.

4our. Leadership Quality Shapes the Employee Experience

Perhaps the strongest emotional discussions involve managers. Employees frequently distinguish between loving their company and struggling with their immediate, incompetent leadership.

Posts describe managers who remove barriers, coach teams, and connect work to patient outcomes as transformative. Conversely, poor leadership is associated with disengagement, turnover, and burnout. Many discussions emphasize that people often leave managers—not companies. For organizations investing millions in culture initiatives, this is an important reminder:

5ive. People Want Less Friction at Work

Perhaps the most interesting finding isn’t about compensation or flexibility. It’s about friction. Employees repeatedly describe obstacles that make great work unnecessarily difficult:

• navigating internal processes
• accessing information
• coordinating across functions
• obtaining decisions
• explaining complex science repeatedly
• asking questions without being labeled as a disruptive
• managing compliance without losing momentum

These aren’t simply operational complaints. They’re productivity problems. And they mirror what healthcare professionals and patients experience outside the organization.

The Strategic Connection

The conversations happening inside pharma resemble those happening outside pharma. Employees want less friction. Physicians want less administrative burden. Patients want treatments that are easier to understand, access, and stay on. Payers want clearer evidence. Commercial teams want simpler customer engagement.

Everyone is asking for the same thing:

Make healthcare easier.

Organizations that solve internal friction often become better at solving external friction.

What This Means for Commercial Leaders

Commercial excellence is evolving beyond messaging. The next competitive advantage won’t come solely from better targeting, more personalized content, or larger media investments. It will come from making every interaction easier.

Easier for employees to collaborate.

Easier for healthcare professionals to understand evidence.

Easier for patients to begin and remain on therapy.

Easier for providers to prescribe.

The companies that reduce friction—internally and externally—will create better employee experiences, stronger customer relationships, and ultimately better health outcomes. Listening to employee conversations isn’t just an HR exercise.

It’s market research. Because the future of pharma may be written first in employee forums long before it appears in quarterly earnings.

The post What Pharma Employees Are Really Saying About Working in Pharma appeared first on World of DTC Marketing.

The Waiting Room Is an Anxiety Environment

The waiting room isn’t a marketing environment. It’s an anxiety-inducing environment. Patients aren’t sitting there thinking, “Tell me about your latest therapy.” They’re wondering whether they have cancer. Whether their bloodwork came back abnormal. Whether they’ll be able to afford treatment. Whether today’s appointment will change their lives. Yet pharma continues to treat these moments of vulnerability as advertising inventory. That should make all of us uncomfortable.

The “Captive Audience” Myth

Waiting-room advertising is built on a simple premise: patients can’t walk away, so they’ll pay attention. That’s precisely the problem.

Calling patients a “captive audience” exposes the fundamental flaw in the strategy. They’re captive because they have no choice—not because they invited your message. No consumer brand would proudly declare that its best marketing works because customers are trapped. Yet healthcare marketing has normalized exactly that.

The industry’s metrics reinforce the illusion:

• Millions of impressions.
• Thousands of physician offices.
• Hours of exposure.

But impressions are not engagement. Exposure is not trust. And trust—not reach—is the currency healthcare desperately needs.

The Evidence Says Patients Need Something Else

Research consistently shows that healthcare visits trigger anxiety. The waiting room itself can contribute to patient stress, affecting a person’s emotional state before the physician even enters the room. Studies of waiting-room environments suggest that calming music, natural imagery, thoughtful design, and other environmental improvements can reduce anxiety and improve the patient experience. One systematic review of 81 studies concluded that thoughtfully designed waiting environments can produce measurable psychological benefits.

Drug advertising isn’t on that list. That shouldn’t be surprising. When people are anxious, their cognitive bandwidth narrows. They’re focused on the upcoming conversation, possible diagnoses, family concerns, insurance questions, and the uncertainty of what comes next. Your brand message is competing with fear. Fear usually wins.

Pharma Doesn’t Have an Awareness Problem

The industry often defends waiting-room advertising by calling it patient education. Most branded campaigns are not primarily educational. They’re designed to increase product awareness, encourage treatment discussions, and ultimately drive prescriptions. That’s marketing.

There’s nothing inherently wrong with marketing. There is something wrong with pretending that marketing is always synonymous with patient education.

If education were truly the objective, companies would invest more heavily in:

• Unbiased disease education.
• Health-literacy programs.
• Shared decision-making tools.
• Medication-affordability resources.
• Physician-patient communication aids.

Instead, many invest in another screen that loops a branded commercial.

Trust Is Pharma’s Scarcest Asset

Waiting-room advertising is particularly shortsighted because pharma companies continue to struggle with public trust. Every interaction matters. Every communication either strengthens credibility or erodes it. Patients increasingly recognize when they’re being marketed to—especially during moments when they feel vulnerable. That recognition doesn’t build confidence. It reinforces the perception that commercial priorities come before patient needs.

In an era when trust has become one of healthcare’s most valuable—and fragile—assets, that’s a remarkably expensive mistake.

What Patient-Centered Marketing Actually Looks Like

Imagine replacing waiting-room advertisements with tools that genuinely help patients:

• Question guides that prepare them for conversations with their physicians.
• Simple explanations of diagnostic tests.
• Medication-affordability resources.
• Treatment decision aids.
• Health-literacy content tailored to the visit they’re about to have.

Those resources could reduce anxiety, improve conversations, and create lasting goodwill. Ironically, they would probably do more for a pharmaceutical company’s reputation than another branded advertisement ever could.

Stop Confusing Access With Permission

The healthcare industry loves talking about being patient-centric. Here’s the test: just because you have access to a patient’s attention doesn’t mean you’ve earned it.

The waiting room belongs to patients—not marketers.

Until pharma companies recognize that distinction, they’ll continue counting impressions while wondering why trust remains so difficult to earn. Sometimes the most patient-centered marketing decision isn’t finding another place to advertise.

It’s knowing when not to advertise at all.

The post The Waiting Room Is Not Your Media Buy appeared first on World of DTC Marketing.

Brand websites are no longer where consumers necessarily end their research journeys. Patients are walking into pharmacies, joining Facebook groups, and arriving at healthcare providers’ offices with well-defined opinions about their treatment options.

What happened?

Online health seekers are getting their information elsewhere.

Before They Reach Your Website, Consumers Are…

• Reading patient stories on Reddit
• Watching physician explainers on YouTube
• Comparing treatment experiences in Facebook groups
• Asking AI-powered tools personalized questions about medicines

By the time patients reach your branded website—if they visit it at all—they may have already answered many of their most important questions. The problem isn’t necessarily media spending. It’s trust.

Trust Is the Real Problem

Over the last decade, trust in traditional healthcare institutions has declined, and pharmaceutical brands are no exception.

When people are asked whom they trust for information about health conditions and treatments, they consistently rank physicians, scientific experts, and people like themselves above corporate websites and branded content.

Healthcare consumers are searching for information, but they don’t trust:

• Buzzwords masquerading as health education
• Articles that emphasize benefits while minimizing side effects
• Content that feels manipulative or deceptive
• Information designed to steer them toward one branded treatment
• Oversized claims unsupported by meaningful context

So, where do they turn? An estimated 58% of Americans research health information online before speaking with their doctor.

During that research, patients compare information across search engines, social media, patient communities, online medical publishers, and AI-powered platforms. Most patients still speak with a healthcare professional before beginning a new treatment. But they now arrive better informed—and often with established opinions about their options.

That’s why the modern pharmaceutical website should not be viewed as the place where the patient journey ends. It is simply another stop along the way.

Healthcare AI Is Changing How Patients Discover Information

Generative AI has transformed how people access health information online. Instead of typing a query into Google and bouncing among ten different websites, patients are increasingly asking AI-powered tools conversational questions such as:

“Which migraine treatments have the fewest side effects?”

“What are patients saying about GLP-1 medications?”

These tools synthesize information from multiple sources, potentially eliminating the need to visit a standalone brand website. Pharma marketers are no longer competing only with other websites for search rankings. They are also competing to become one of the credible sources AI platforms use when answering patients’ questions.

That requires content that is educational, objective, and genuinely helpful—not content optimized solely to promote a product.

People Trust People More Than Brands

Internal research and public surveys have repeatedly reached the same conclusion: consumers place greater trust in people than in corporations. According to Edelman’s Trust Barometer, 67% of respondents identified “a person like yourself” as a credible source of information. Among individual sources, only “my doctor” ranked higher.

In healthcare specifically, physicians remain the most influential source of treatment information. But before medical appointments, patient reviews, disease communities, advocacy organizations, and independent medical publishers are gaining influence.

Patients want to hear from other people. That helps explain why physicians, patient advocacy groups, and independent health publishers are building audiences while many branded websites struggle to generate meaningful engagement.

Conversations create trust more effectively than campaigns.

Here’s what leading DTC marketers can do about it.

Put Education Before Promotion

Providing genuine educational value before introducing a treatment option demonstrates patience, confidence, and humility. The most effective patient websites help people understand their condition, symptoms, diagnostic journey, and available treatment approaches before presenting a particular product.

Patients should leave the site feeling better informed—not simply more exposed to the brand.

Partner With Real People

Medical experts, pharmacists, patients, caregivers, and advocacy organizations can help pharma companies communicate in ways that feel more credible and human. These partnerships should go beyond endorsements. They should give trusted voices an opportunity to answer real questions, acknowledge uncertainty, and discuss the everyday realities of living with a condition or taking a treatment.

Authenticity cannot be manufactured by a brand team. It has to come from people with relevant knowledge and lived experience.

Create Content People Actually Search For

Patients do not always search using the branded terms or clinical language marketers expect. Talk to patients. Listen to the words they use. Understand the questions they ask at every stage of the treatment journey.

Those questions may include:

• How will this medicine affect my daily life?
• How much will it cost?
• What happens if it doesn’t work?
• How do the side effects compare with other treatments?
• What have other patients experienced?
• What should I ask my doctor?

Content that answers real patient questions will attract more meaningful traffic than pages built primarily around brand messaging.

Be Transparent

Patients do not trust exaggerated claims or selectively presented information. Branded websites should not be afraid to discuss risks, side effects, costs, access challenges, and treatment alternatives. When appropriate and compliant, they should help patients understand how available options differ.

Honesty does not weaken a brand. In healthcare, it can make the brand more credible.

Optimize for AI Discovery

AI optimization is not simply a new version of keyword stuffing. Content is more likely to be discovered, understood, and cited by AI platforms when it is:

• Clearly organized
• Written in direct, natural language
• Supported by credible evidence
• Specific about benefits and risks
• Consistent across pages
• Regularly reviewed and updated
• Educational rather than excessively promotional

The goal should not be to manipulate an AI system into mentioning a product. It should be to publish information credible enough to deserve inclusion in an answer.

Earn the Right to Be Part of the Journey

Patients once moved predictably from search engines to health publishers and then to pharmaceutical websites. That journey is now fragmented. Today’s patients use AI tools, social media, online communities, healthcare professionals, patient reviews, and independent publishers to evaluate treatment options—sometimes before they have ever heard of your brand.

The brand website still matters, but its role has changed. It must support a broader information journey rather than assume it is the final destination. At the end of the day, patients want what everyone wants: the ability to make better, more confident decisions.

By prioritizing patient education over direct promotion, pharmaceutical marketers have an opportunity to earn something that media spending alone cannot buy.

Trust may be the most valuable currency in healthcare today.

The post Why More Online Health Seekers Are Ignoring Pharma Websites appeared first on World of DTC Marketing.

Paul, a friend of mine whom I have known for over 20 years, has worked on several blockbuster drug launches. He understood the market and its key players and was responsible for sustained growth over the drug’s lifecycle. When the product came off patent, his company made him look for another job within the company, which he quickly found. Today, Paul, still many years away from retirement, is looking for work.

Too many people are staying silent as ageism and “fitting in” take center stage at pharma company hiring practices. Make no mistake: there is a LOT of talent and experience out there, but many hiring managers are afraid to hire people with so much experience because it might reveal their own shortcomings.

Despite decades of experience leading successful launches, developing high-performing brands, and navigating some of the industry’s most competitive markets, many seasoned pharma marketers struggle to find opportunities. Increasingly, companies appear to prioritize lower-cost talent, narrowly defined functional expertise, or experience with the latest digital platforms over the strategic marketing capabilities that have historically driven successful launches.

The irony is difficult to ignore.

The pharma industry has never faced greater commercial complexity. Market access has become more challenging. Physicians are overwhelmed with information. Patients are more informed than ever. Artificial intelligence is changing how healthcare professionals gather information. Competition is increasing across nearly every therapeutic area. These are precisely the conditions that demand stronger marketing leadership—not less.

Technology can accelerate execution, but it cannot replace strategic thinking.

Technology can accelerate execution, but it cannot replace strategic thinking.

Data can identify patterns, but it cannot determine how to build trust with physicians or create a compelling value proposition that resonates with multiple stakeholders. Digital tools are powerful enablers, but they are not substitutes for marketers who understand how brands are built over years, not quarters.

The industry often talks about becoming more patient-centric, more innovative, and more commercial. Yet too often, it overlooks professionals who have spent their careers doing exactly that.

The industry often talks about becoming more patient-centric, more innovative, and more commercial. Yet too often, it overlooks professionals who have spent their careers doing exactly that.

This is not an argument against hiring younger talent. Every industry needs new perspectives, digital fluency, and fresh ideas. The strongest organizations combine those strengths with the judgment and pattern recognition that only experience can provide.

Great pharma marketing has always been a balance of science, strategy, creativity, and execution. When companies lose that balance, they risk more than disappointing product launches. They risk losing the institutional knowledge that helps transform promising therapies into enduring brands.

The next blockbuster drug will not succeed because of its marketing technology stack alone. It will succeed because talented people know how to connect groundbreaking science with the needs of physicians, patients, payers, and healthcare systems.

The next blockbuster drug will not succeed because of its marketing technology stack alone. It will succeed because talented people know how to connect groundbreaking science with the needs of physicians, patients, payers, and healthcare systems.

Perhaps it is time for the industry to ask a simple question:

If the people who built yesterday’s blockbuster brands are no longer considered valuable, who will build tomorrow’s?

The post Pharma Is Sidelining the People Who Built Its Biggest Brands appeared first on World of DTC Marketing.

Pharma companies spend $475 million to $830 million on launch-related activities. When launches fail to meet expectations, companies destroy significant value, erode brand equity, and deprive patients of treatments that can improve their lives.

Why do promising new therapies underperform at launch?

Four commercial reasons stand out:

• Market-access barriers: 30%
• Lack of patient insights: 27%
• Weak differentiation: 26%
• Stakeholder misalignment: 13%

External factors are responsible for the remainder of the failures.

Market access is often the most critical factor.

If patients cannot access therapy, they will not use it. High copays, prior authorization requirements, narrow coverage criteria, and reimbursement delays can stifle demand, even when physicians are aware of a product’s clinical benefits.

Case in point: PCSK9 cholesterol-lowering therapies. Despite their clinically significant impact on LDL cholesterol levels, high list prices—nearing $14,000 per year at launch—led many payers to institute restrictive formulary policies. Physicians submitted prescriptions that were denied. Patients dropped out of treatment. Sales suffered.

It took significant price cuts and removal of access barriers to improve uptake.

The patient journey is part of the product.

Too many launch teams view the patient journey through the lens of communications and education. In fact, it is a vital component of every launch strategy. From diagnosis to sustained use, patients can face numerous obstacles. They may struggle to see a specialist, obtain insurance coverage, travel to a hospital or infusion center, manage side effects, or understand why they need to stay on therapy. Each of these barriers can dampen initiation and adherence rates, derailing launch performance.

Consider Nerlynx, a HER2-positive breast cancer medication. Nerlynx addressed a clear clinical need. But many patients experienced severe gastrointestinal side effects that led them to stop treatment. Physicians and patients were ill-equipped to prevent or manage these effects ahead of time, causing sales to lag.

Prevention always starts with understanding how patients encounter and engage with therapies across multiple channels. Patient education, prophylactic treatment, and adherence support could have minimized discontinuation due to gastrointestinal side effects.

Clinical data is just one part of differentiation.

When faced with multiple treatment options, physicians typically reach for medicines they know and trust. Positive trial results are not enough to change prescribing habits. Successful launches require clear answers to three questions:

1. Why should physicians prescribe your product?
2. Why should payers cover your product?
3. Why should patients want to use your product?

Answers to these questions will differ by stakeholder. Physicians may care about clinical efficacy, safety profile, and dosing convenience. Payers may prioritize comparative efficacy, budget impact, and avoided costs. Patients may value symptom improvement, convenience, side effects, and quality of life.

An effective value proposition distills clinical data into benefits that resonate with each stakeholder group. Additionally, it requires consistent messaging across publications, field teams, medical education programs, digital platforms, and patient services.

Here are five priorities that can help companies improve launch performance.

1ne. Start market-access planning before launch

Successful market access begins during drug development, not after a product receives regulatory approval. Key messages, endpoints, health-economic data, and pricing assumptions should be validated with payers throughout Phase II and Phase III clinical trials.

Manufacturers can also establish flexible risk-sharing mechanisms in advance, including bridge programs, patient-assistance funds, outcomes-based agreements, and more.

2wo. Align the organization around a shared vision for launch

Launch plans should be developed using a common dataset drawn from clinical development, market access, medical affairs, commercial, regulatory, and patient-support teams. External stakeholders should be engaged early and often.

Medical affairs can validate positioning and identify educational priorities. Market-access intelligence should inform financial forecasting and field training. Patient insights should define support services and key messaging.

Working in silos wastes resources and propagates misaligned expectations. Collaborating too little increases the risk that assumptions will be challenged after launch.

The other issue plaguing product launches is poor hiring decisions based on fit rather than knowledge. Too many organizations would rather hire robots to go out and do rather than people who ask intelligent questions, which many managers take as pushback.

3hree. Understand the patient journey from symptoms to treatment

Commercial organizations must understand the patient journey from symptom onset through diagnosis, referral, coverage, treatment initiation, and maintenance. Preferably, companies should do this before launch.

This insight should then be translated into programs to support patients wherever they encounter hurdles. Solutions may include patient navigators, financial assistance programs, nurse helplines, side-effect education, adherence initiatives, or better referral processes.

4our. Develop a differentiated value story and test it with key audiences

From pricing to patient support, differentiation should be stress-tested with external stakeholders before launch day. If your organization cannot clearly articulate why physicians should prescribe the product, payers should cover it, and patients should use it — chances are you either need more data or a better story.

Keep in mind that more communication is not always the solution. It is about driving behavior change by providing each stakeholder with a relevant reason to change.

5ive. Execute with flexibility and learn as you go

Finally, successful launches require flexibility. Teams should track awareness, prescribing, fulfillment rates, access delays, and patient drop-off from diagnosis through the first year of treatment. When performance falls short, teams should investigate root causes and implement countermeasures.

Similarly, digital, remote, and field-based engagement should work together seamlessly. Messaging may differ by channel and stakeholder, but the underlying data should always be current. Companies should reach customers where they are willing and able to engage, while leveraging the strongest available evidence to personalize that experience.

Learn from reality.

Commercial excellence starts with asking hard questions about how the science applies to reimbursement, clinical care, and patients’ day-to-day realities. It requires launching with a shared understanding of the market and creating systems to learn from experience (both internal and external) while there is still time to change course.

Drug launches are hard. They are also predictable. By identifying weaknesses early, pharma companies can improve how they prioritize resources and adapt their strategies before launching… and not just after.

The post Why 60% of Drug Launches Fail appeared first on World of DTC Marketing.

When EMRs were first introduced, the vision was compelling. Digital records would improve care coordination, reduce medical errors, lower costs, and provide clinicians with immediate access to patient information. While EMRs successfully digitized healthcare information, they also introduced new challenges—expanding documentation requirements, creating increasingly complex workflows, and forcing clinicians to spend more time with keyboards than with patients.

Artificial intelligence (AI) presents an opportunity to fulfill the vision we originally had for EMRs. AI is not a replacement for the EMR. Instead, it has the potential to fundamentally transform how clinicians interact with it.

The Dream Versus the Reality

When hospitals and health systems began implementing EMRs, the expected benefits included:

• Better clinical decision-making
• Elimination of duplicate documentation
• Seamless information exchange
• Fewer medical errors
• Improved population health management
• Streamlined operational workflows

To be fair, EMRs have delivered meaningful improvements. Clinicians can access patient information faster than ever before. Computerized physician order entry has reduced many prescribing errors, and clinicians now have unprecedented amounts of clinical information available at the point of care.

Yet those gains have come with unintended consequences, including:

• Physician burnout
• Expanding documentation requirements
• Fragmented and inefficient clinical workflows

One of the most common frustrations clinicians express is that today’s EMRs seem optimized for billing rather than patient care. Although improving care was always the objective, many clinicians feel the technology has had the opposite effect.

AI Changes the EMR–Clinician Relationship

Historically, clinicians have been forced to adapt their workflows to meet the needs of the EMR. AI has the potential to reverse that dynamic. Instead of requiring clinicians to navigate dozens of screens to locate relevant information, AI can surface the right information at the right time. Instead of documenting every patient encounter manually, AI can generate clinical notes automatically. Instead of clicking through menus to answer clinical questions, clinicians can simply ask conversational questions and receive contextual responses.

The EMR remains the system of record. AI becomes the intelligent interface.

EMRs Store Data. AI Unlocks Clinical Intelligence.

EMRs have become exceptionally good at storing information. They have been far less successful at helping clinicians interpret and act upon that information. By layering AI capabilities on top of existing EMRs, healthcare organizations can:

• Automatically summarize complex patient histories
• Highlight clinically relevant trends
• Identify gaps in care
• Surface critical laboratory results and documentation
• Recommend evidence-based treatment options
• Detect potentially harmful medication interactions or changes
• Improve care coordination across multidisciplinary teams

In short, while EMRs capture data, AI helps transform that data into actionable clinical intelligence.

Reducing the Documentation Burden

Perhaps no aspect of the EMR frustrates physicians more than documentation. After a full day of patient care, many clinicians spend hours completing notes and administrative documentation.

AI-powered ambient documentation offers a fundamentally different approach.

By listening to conversations between clinicians and patients, AI can automatically generate structured clinical documentation. Physicians remain responsible for reviewing and approving the final documentation, but much of the manual work disappears. The value extends beyond efficiency.

Less time documenting means more time engaging with patients—and less time completing charts after hours.

Unlocking the Hidden Value of Clinical Data

Healthcare organizations have spent decades collecting enormous volumes of clinical data. Since the adoption of EMRs, that information has accumulated in both structured and unstructured formats. Unfortunately, much of it remains underutilized. AI changes that equation.

Its ability to analyze vast datasets allows healthcare organizations to extract insights that were previously impossible to generate manually.

Applications include:

• Population health management
• Predicting patients at risk for clinical deterioration
• Improving operational efficiency through predictive analytics
• Accelerating revenue cycle processes
• Enhancing quality measurement and reporting
• Advancing clinical research

EMRs helped healthcare organizations collect data.

AI can finally help organizations put that data to work.

AI Is Not a Silver Bullet

Despite its promise, AI is not a cure-all. Healthcare organizations must address several critical challenges before AI can be deployed responsibly and at scale, including:

• Data quality and standardization
• Interoperability across systems
• Governance and regulatory compliance
• Algorithm transparency
• Patient privacy
• Cybersecurity
• Clinical validation and human oversight

Strong governance will be essential to ensure AI systems remain transparent, reliable, and aligned with clinical best practices. Most importantly, AI should integrate naturally into existing clinical workflows rather than requiring clinicians to learn entirely new ways of working.

The Future of Electronic Medical Records

The EMRs of tomorrow will probably look remarkably similar to those we use today. Healthcare organizations are unlikely to replace their enterprise EMR platforms with entirely new AI-native systems. Instead, AI will increasingly be layered on top of existing platforms, making them dramatically more intelligent.

Future EMRs will:

• Answer clinical questions conversationally
• Generate documentation automatically
• Anticipate clinicians’ information needs
• Coordinate administrative tasks
• Improve patient communication
• Continuously learn from organizational data

Rather than navigating endless screens, clinicians will receive the information they need precisely when they need it. Instead of dividing their attention between patients and computer screens, they can devote more of their focus to what matters most—the patient sitting in front of them.

Bringing It All Together

When healthcare leaders embraced electronic medical records, their goal was never simply to replace paper with digital files. The objective was to make healthcare:

• Smarter
• Safer
• More connected

That vision remains just as relevant today. By augmenting EMRs with artificial intelligence, healthcare organizations have the opportunity to:

• Give clinicians more time with patients
• Reduce physician burnout
• Improve clinical decision-making
• Enhance quality and patient outcomes
• Lower administrative costs

For the first time since EMRs became mainstream, we have technology capable of delivering on the original promise of digital healthcare. The future of the EMR isn’t about replacing it. It’s about making it intelligent.

The post Can AI Finally Deliver on the Promise of Electronic Medical Records? appeared first on World of DTC Marketing.

Doctors are no longer raising awareness for brands; patients are. Physicians are often playing catch-up to educate patients on options. This fundamentally changes the marketing equation. 

Pharma Has the Wrong Funnel Topology

Most pharma marketers are still optimizing for old-school marketing metrics such as impressions, frequency, SOV, click-through rates, and website visits. These are GREAT measures for things you POST. They don’t help you understand how your brand showed up (or didn’t show up) in the hours and conversations that came before step 1 above.

The new patient journey looks less like this: symptom awareness > Google > Reddit > YouTube > ChatGPT > patient advocacy group > find a specialist > doctor appointment > Insurance research > Second opinion and more. Attributing a website visit or content download to a single doctor visit doesn’t capture the full scope of this journey.

 Competitive Advantage is Now AI Visibility

Billions of questions are being asked of AI engines daily:

1ne: “What medicines treat arthritis?” 

2wo: “Drug A vs Drug B, which is better?”

3hree: “What are the side effects of Drug C?” 

4our: “What questions should I ask my doctor?” 

AI isn’t stealing patients from search engines. AI is an additional “layer” of healthcare discovery. If your clinical evidence, marketing collateral, and website aren’t built in a way that allows AI to “see” it and reference it accurately, you’re going invisible on one of the largest growth information channels in history. SEO won’t cut it. Unless you build for answer engines, you’ll be evaporating competitive advantage before the game even begins. 

Trust Will Become the Ultimate Marketing KPI: Healthcare = Trust, Pharma Marketing = Attention

Attention rarely buys trust (at least in healthcare). But things are starting to change. Today, patients are starting to reward brands who: educate vs. persuade, acknowledge what they don’t know, empathize, simplify complex topics, and provide trustworthy resources

Here’s a tighter, more LinkedIn-native version with improved flow, stronger transitions, and cleaner formatting while preserving your core ideas.

The brands that sell the least may ultimately earn the most.

Because trust—not promotion—is becoming pharma’s most valuable marketing asset.

And trust drives:
• Patient adherence
• Physician confidence
• Long-term brand value

Trust is the new marketing currency.

Better Marketing Isn’t About Better Ads. It’s About Better Questions.

Stop asking:

“How do we get more impressions?”

Start asking:

“What questions are patients too afraid to ask?”

Instead of:

“How do we increase CTR?”

Ask:

“Where do patients feel uncertain during the treatment journey?”

And then ask:

“How can we eliminate that uncertainty?”

Don’t market to patients.

Solve patients’ problems.

AI Won’t Replace Pharma Marketers. Content-Only Marketers Will Become Irrelevant.

The marketers who thrive won’t simply create blog posts.

They’ll become:

• Insight detectives who uncover unmet patient needs.
• Translators who turn complex medical evidence into understandable patient resources.
• Experience designers who map content to real patient journeys.
• Trust builders who lead with empathy.
• Orchestrators who connect commercial, medical, digital, and regulatory teams.

AI will become exceptionally good at producing content. What it cannot easily replicate is human judgment. It doesn’t understand FDA regulations, scientific nuance, patient psychology, or the ethical tradeoffs that define pharmaceutical marketing. As AI creates more content, human expertise becomes more—not less—valuable.

Welcome to Pharma Marketing 2.0

Tomorrow’s marketers will:

• Build content for AI systems and human audiences.
• Measure educational impact alongside marketing performance.
• Bring commercial, digital, medical, and regulatory teams together much earlier.
• Treat patient intelligence with the same importance as market intelligence.
• View trust as a strategic asset—not an intangible outcome.

Success won’t necessarily require larger budgets. It will require a deeper understanding.

One Question Every Pharma Marketer Should Ask

Imagine every patient entering your therapeutic area spends 30 minutes talking with an AI assistant before seeing a physician. Could your brand confidently say that the AI is accurately representing your science, evidence, and approved messaging? If you’re not confident in that answer, your competitors have an opportunity. Every day that gap remains, AI continues learning—from whatever information is available. That information may be incomplete, outdated, or simply not yours.

The playing field is shifting now

AI is already narrowing the information gap between patients and physicians in ways our industry has discussed for years. If pharma marketers want to remain relevant, we can’t simply create more content. We need to help AI understand our science as accurately as we do.

The post The Pharma Marketing Playbook is Over. AI Didn’t Do It. Patients Did. appeared first on World of DTC Marketing.

Business Model: Patient-First Prescription Cooperative (PPC)

Core Idea

Create a membership-based organization that purchases medications directly from manufacturers (or licensed wholesalers), contracts with independent pharmacies, and passes savings to members with a fixed, transparent markup. The cooperative functions similarly to a warehouse club combined with a pharmacy benefit manager (PBM), but without rebate incentives.

Revenue Model

Revenue comes from four predictable sources:

• Monthly membership fee ($5–15/month)
• Small transparent markup (5–10%) on medications
• Employer-sponsored memberships
• Administrative fees for medication management services

No revenue is earned from manufacturer rebates.

How It Saves Money

1ne. Eliminate PBM Rebates

Today’s system often works like this:

Manufacturer → PBM → Insurance → Pharmacy → Patient

Every intermediary may receive fees or rebates. Instead:

Manufacturer → Cooperative → Pharmacy → Patient

This removes several layers of cost.

2wo. Transparent Pricing

Every prescription would display:

• Acquisition cost
• Distribution cost
• Pharmacy dispensing fee
• Cooperative margin

Example:

Manufacturer price: $22

Shipping/storage: $3

Pharmacy fee: $8

Co-op margin: $2

Final price:
$35

Instead of the same drug costing anywhere from $35–120 depending on insurance.

3hree. Direct Manufacturer Contracts

The cooperative negotiates directly with manufacturers based on total purchasing volume.

Manufacturers benefit because:

• lower marketing costs
• predictable demand
• guaranteed payment
• reduced PBM negotiations

4our. Generic First

Clinical pharmacists automatically recommend FDA-approved generics whenever appropriate.

Savings often exceed 80%.

5ive. Subscription Medications

For chronic illnesses:

• diabetes
• hypertension
• cholesterol
• asthma

Patients pay a monthly subscription. Example: $45/month. Unlimited eligible generic medications. Free mail delivery. Medication reminders. Pharmacist consultations. This smooths costs for patients while creating recurring revenue.

Technology Platform

A mobile app would include:

• Price comparison
• Prescription transfer
• Medication adherence reminders
• Automatic refill scheduling
• Drug interaction alerts
• Telepharmacy consultations
• Prior authorization assistance

AI Component

AI could:

• Recommend lower-cost therapeutic equivalents
• Identify manufacturer assistance programs
• Predict medication adherence risks
• Suggest 90-day fills when economical
• Optimize inventory purchasing

Additional Revenue Opportunities

Instead of increasing drug prices, the company could sell value-added services:

• Medication therapy management
• Employer wellness programs
• Chronic disease coaching
• Telehealth visits
• Pharmacogenomic testing
• Home delivery

Employer Partnership

Employers could pay: $8–12 per employee per month. Employees receive:

• discounted prescriptions
• free generics
• pharmacist access
• home delivery

Employers benefit through lower healthcare spending and reduced absenteeism.

Manufacturer Incentives

Manufacturers gain:

• guaranteed purchase volume
• lower customer acquisition costs
• predictable forecasting
• faster payment
• direct access to patient demand

Instead of spending heavily on rebates and marketing, they compete on transparent pricing.

Regulatory Advantages

The cooperative could operate as a licensed pharmacy network while complying with existing federal and state pharmacy regulations. It could also leverage:

• 340B partnerships where appropriate
• value-based purchasing agreements
• biosimilar substitution
• electronic prescribing integration
• Interstate mail-order pharmacy licensing

Example Economics

For a drug with a traditional retail price of $120:

Challenges

The model would need to overcome several hurdles:

• PBM and insurer resistance due to disrupted revenue streams.
• Difficulty negotiating favorable prices without sufficient purchasing volume in the early stages.
• State-by-state pharmacy licensing and compliance requirements.
• Integration with insurance plans for patients who want to use benefits rather than cash pricing.
• Capital requirements for inventory, technology, and distribution.

Long-Term Vision

Over time, the cooperative could evolve into a healthcare platform that combines prescription fulfillment, telehealth, chronic disease management, and preventive care. By scaling purchasing power and maintaining transparent pricing, it could lower medication costs while generating sustainable revenue through memberships and service fees rather than hidden markups.

The key differentiator is aligning financial incentives with affordability: the organization succeeds by increasing membership, improving medication adherence, and reducing overall healthcare costs—not by raising the prices patients pay for prescriptions.

The post Could This Model Work For Lowering Prescription Drug Costs? appeared first on World of DTC Marketing.